Navigation Links
Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
Date:1/15/2009

CAMBRIDGE, Mass., Jan. 15 /PRNewswire/ -- Peptimmune, Inc. ("Peptimmune"), a privately held biotechnology company, announced today that it has granted Novartis (NYSE: NVS) an exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301, Peptimmune's multiple sclerosis drug candidate. In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. made an equity investment in Peptimmune.

In the event that Novartis exercises the option to PI-2301, Novartis would assume the global clinical development, manufacturing, and marketing of PI-2301 and all associated costs. Peptimmune would receive payments upon the option exercise and upon successful completion of certain development, regulatory, and commercial milestones. These payments together could total more than $500 million. In addition, Peptimmune shall be eligible to receive royalties on product sales. Additional terms were not disclosed.

"We believe that Novartis represents an outstanding future partner for Peptimmune and the global development of PI-2301. This option agreement provides Peptimmune with access to both Novartis' world class development expertise and the necessary capital to invest in this proprietary product," said Thomas P. Mathers, President and CEO of Peptimmune.

Todd Foley, Managing Director at MPM Capital commented, "Peptimmune and its world-leading expertise in peptide copolymers represent an attractive investment opportunity."

About PI-2301

PI-2301 is a peptide copolymer developed using Peptimmune's novel platform peptide chemistry. PI-2301 is designed to enhance the regulatory response of the immune system, thereby controlling the pathogenic autoimmune response in certain diseases. PI-2301 is currently in Phase 1b development by Peptimmune.

About Peptimmune (www.peptimmune.com)

Peptimmune is a clinical stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders. These therapies target MHC Class II molecules and modulating immune responses. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP(TM) Technology to design peptides and peptide mixtures.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Peptimmune Announces the Second Close of Series D Private Financing
2. Tufts receives NIH grant to study obesity prevention in new immigrants
3. Floridas Uninsured and Underinsured to Benefit from Statewide Grants
4. Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008
5. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
6. The National Parkinson Foundation Awards Five Grants for the Falls Prevention Initiative
7. Life Sciences Discovery awards health research program grants
8. Blue Cross Foundation Awards $660,000 in Grants to Improve Community Health
9. FDA Grants NeoVistas Request to Utilize Novel Wet AMD Treatment in Compassionate Case
10. UnitedHealth Group Grants to Help Students and Educators Combat Childhood Obesity
11. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , ... February 22, 2017 , ... Pet obesity in ... 54% of dogs, according to the Association for Pet Obesity Prevention (APOP). During the ... pet food issues such as the benefits of corn and grains, value of raw ...
(Date:2/22/2017)... ... February 22, 2017 , ... In today’s world, ... solutions on the market, it is easy to start feeling frustrated and confused. ... offers a complimentary security consultation. , Home Security Hardware Choices, There are innumerable ...
(Date:2/22/2017)... OAKLAND/SAN FRANCISCO BAY AREA - NORTHERN CALIFORNIA (PRWEB) , ... ... ... Forum (PMF) aims to expand the pipeline and the number of African ... support that encourages medical students and residents to pursue their careers as physicians ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... Marc Philpart, senior director at PolicyLink, will be the keynote speaker at its ... Boys and Men of Color Framework, which develops comprehensive strategies to create and ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas ... around Tarrant County, is embarking on a six month charity event aimed at raising ... cancer. , Cancer is one of the deadliest diseases in America; more than 7.5 ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... and HAMBURG, Germany , February 22, 2017 ... precision oncology headquartered in Hamburg, Germany and ... research institution, announced today a collaboration to support the first Indian ... research. ... Indivumed signed an agreement with an initial three-year term. The collaboration ...
(Date:2/22/2017)... 22, 2017  Soligenix, Inc. (Nasdaq: ... biopharmaceutical company focused on developing and commercializing products ... unmet medical need, announced today that its proprietary ... European patent for the treatment of psoriasis. The ... treatment of skin conditions, complements the method of ...
(Date:2/21/2017)... 21, 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer ... prospects of the market globally. The stakeholders of ... the manufacture and commercialization of various mass spectrometer ... planning to enter this market. This report comprises ...
Breaking Medicine Technology: